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Equine inﬂuenza (EI) is a major respiratory disease of the horse
induced by the highly contagious equine inﬂuenza virus (EIV).
Worldwide, diverse EI vaccines are available commercially. The
EIV strain, adjuvant composition and vaccine technology differs
greatly. The use of the same EI vaccine throughout the life of a
horse is unlikely, due to change of ownership, veterinary practi-
tioner, location and/or vaccine availability. The compatibility of
different EI vaccines has rarely been studied but is of great
importance as immunisation failure could favour EIV dissemina-
tion. Study aims: To determine the impact of mixed EI vaccination
on protective immunity to EIV in horses and to measure herd
immunity in Hong Kong (HK). Methods: HK has approximately
1,250 race horses with around 450 new horses arriving each year.
Imported racehorses must have been vaccinated with an
approved EI vaccine, irrespective of their point of origin. All
horses are given a new primary course on arrival with a unique
ISCOM matrix adjuvanted EI vaccine and are vaccinated twice a
year thereafter. EI-speciﬁc antibody titres were measured by
single radial haemolysis (SRH) assay (A/eq/South Africa/4/03 EIV
strain) in 1050+ archived sera collected between 2010 and 2014
from 129+ horses. Objectives: 1) to determine the SRH antibody
titre in serums from HK resident horses (i.e. in HK for at least 1.5
year), 2) to evaluate the antibody titre on arrival at HK in relation
to their country of origin, 3) to measure the effect of post-arrival
mandatory EI primary vaccination and 4) to compare this
response with antibody levels measured in HK resident horses.
Results: Preliminary results indicates that the average yearly SRH
antibody titre for HK resident horses was 113±34mm2 (n¼467),
with only 15% of horses below the clinical protection threshold
(i.e. 85mm2) and less than 3% of horses below 50mm2. A sig-
niﬁcant increase was detectable (p-value<0.00004) after each
immunisation boost (maximum average titre of 128±42mm2 in
October, n¼55). The average SRH antibody titre in the week
following importation to HK (and prior the mandatory EI
vaccination in HK) was 180±40mm2 (n¼79), with results in
horses originating in Australia signiﬁcantly higher (207±36mm2,
n¼10, p-value ¼ 0.0281) than horses from New Zealand
(171±34mm2, n¼42), Great Britain (168±38mm2, n¼17) or
Ireland (172±31mm2, n¼3). SRH antibody titres at the time of
importation were maintained for around 75 days (Figure 1) due0737-0806/$ e see front matterto post-importation immunisation before decreasing slowly to
reach the levels of HK resident horses (around 200-225 days post
importation). Conclusion: There are few large scale sero-epide-
miological investigations monitoring horses after EI vaccination.
Preliminary analysis indicates that a large proportion (85%) of
the HK horse population has protective SRH antibody titre,
which should provide efﬁcient herd immunity and protection
against EI. The impact of mixed EI immunisation is currently
being analysed.
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Equine Inﬂuenza (EI) is an important respiratory disease of the
horses. Numerous EI vaccines are commercially available world-
wide and an accurate evaluation of their efﬁcacy is required
through clinical trials conducted in the natural host challenged by
experimental infection with equine inﬂuenza virus (EIV). Room
nebulisation is one of the recognised/chosen methods to deliver
an EIV infectious aerosol during the in vivo challenge phase of EI
vaccine studies. This method has been frequently used in the last
few decades; it is well tolerated, requires minimal animal
manipulation and has a demonstrated efﬁcacy. However, it pre-
sents inherent limitation, such as the difﬁculty to accurately
determine the EIV dose inhaled by an individual animal.
Furthermore, the suspected decreased pathogenicity of recent
Florida Clade 2 (FC2) EIV isolates have increased the
